Home Markets Eli Lilly’s Zepbound outperforms Novo Nordisk’s Wegovy in weight loss trial

Eli Lilly’s Zepbound outperforms Novo Nordisk’s Wegovy in weight loss trial

May 12, 2025 comments off

Original source: https://www.investing.com/news/stock-market-news/eli-lillys-zepbound-outperformsnovo-nordisks-wegovy-in-weight-loss-trial-4037781

You May Also Like

Is TTF gas fairly priced as Hormuz, winter risks keep prices elevated?

UBS sees better bond carry in 3-5 year debt after global selloff

Milei finds unity in pushback against Falkland Islands oil project

UBS: Commodities can add diversification as inflation, geopolitical risks rise

U.S. may struggle to build power fast enough to meet rising demand, Barclays says

OpenAI acknowledges ’wiki incident’ and need for more transparency around unintended AI behavior